Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF) posted its quarterly earnings data on Thursday. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.96), Zacks reports. Zealand Pharma A/S had a net margin of 70.06% and a return on equity of 48.10%. The company had revenue of $5.33 million during the quarter, compared to analyst estimates of $3.77 million.

Zealand Pharma A/S Trading Down 1.4%

Shares of OTCMKTS ZLDPF traded down $0.76 during mid-day trading on Friday, hitting $53.52. The company’s stock had a trading volume of 671 shares, compared to its average volume of 3,938. Zealand Pharma A/S has a one year low of $35.93 and a one year high of $83.12. The company’s fifty day simple moving average is $46.61 and its 200-day simple moving average is $62.88. The company has a debt-to-equity ratio of 0.02, a current ratio of 23.57 and a quick ratio of 23.57. The stock has a market cap of $3.83 billion, a price-to-earnings ratio of 3.91 and a beta of 0.87.

Analyst Ratings Changes

A number of brokerages recently weighed in on ZLDPF. William Blair reissued a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Finally, BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Three investment analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.